Securities Lawsuit Filed Against Organon & Co.

Strategic Insights -

A leading securities law firm has filed a lawsuit against Organon & Co. (NYSE: OGN) and certain of its senior executives for potential violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey.

Key Takeaways:

  • The lawsuit claims that Organon assured investors it would maintain its dividend, but instead shifted its capital allocation priority to reduce debt after acquiring Dermavant in October 2024.
  • Organon's stock declined roughly 27% after the company announced a dividend cut from $0.28 per share to $0.02 per share on May 1, 2025.
  • The lawsuit seeks to represent investors who purchased Organon securities, and claim damages for alleged securities law violations.
  • BFA, the law firm behind the lawsuit, has a history of success in securities class actions, recovering over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.
  • Investors who purchased Organon stock may have legal options and are encouraged to submit their information to the firm for potential representation.

Statistics:

  • Organon's stock price declined by 27% from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.
  • The lawsuit claims damages for alleged securities law violations on behalf of investors who purchased Organon securities.
  • BFA has recovered over $1.32 billion in value from various securities class actions, including $900 million from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Sources:

  • "Leading Securities Law Firm Announces the Filing of Lawsuit Against Organon & Co. and Certain of its Senior Executives" (GLOBE NEWSWIRE, July 18, 2025)
  • "Organon Declines on Slashing Dividend Payout" (Law360, May 1, 2025)
  • "BFA Secures Over $900M for Tesla Investors" (Chambers USA, 2025)
  • "BFA Secures Over $420M for Teva Investors" (The Legal 500, 2025)